Prolyl hydroxylase 3 overexpression accelerates the progression of atherosclerosis in ApoE-/- mice

Hui Liu1, Yanfei Xia1, Beibei Li1

  • 1Qilu Hospital of Shandong University, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Jinan, Shandong 250012, China.

Insights

Prolyl hydroxylase domain-3 (PHD3) promotes atherosclerosis by increasing plaque size and inflammation. Inhibiting PHD3 reduces endothelial cell apoptosis, suggesting it as a therapeutic target for cardiovascular disease.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Pathophysiology

Background:

  • Prolyl hydroxylase domain-3 (PHD3) is an iron-dependent dioxygenase regulating Hypoxia-inducible factor 1-alpha (HIF-1α).
  • PHD3 expression is elevated in cardiovascular diseases, but its role in atherosclerosis remains unclear.

Purpose of the Study:

  • To investigate the effect and mechanism of PHD3 in the development of atherosclerosis.
  • To explore the role of PHD3 in endothelial cell apoptosis and inflammatory responses in vitro.

Main Methods:

  • Apolipoprotein E-deficient (ApoE-/-) mice were treated with lentivirus to overexpress or inhibit PHD3.
  • High-fat diet was administered to induce atherosclerosis.
  • In vitro studies utilized human umbilical vein endothelial cells (HUVECs) treated with oxidized low-density lipoprotein (ox-LDL).

Main Results:

  • PHD3 overexpression in ApoE-/- mice led to larger aortic atherosclerotic lesions, increased macrophage and smooth muscle cell infiltration, and enhanced plaque apoptosis.
  • Overexpression of PHD3 upregulated inflammatory markers including ICAM-1, VCAM-1, MCP-1, IL-1β, and TNF-α.
  • In vitro, PHD3 overexpression activated the MAPK signaling pathway (ERK1/2 and JNK), while PHD3 inhibition reduced ox-LDL-induced HUVEC apoptosis.

Conclusions:

  • PHD3 plays a significant role in promoting atherogenesis, beyond its known function as an HIF-1α regulator.
  • PHD3 contributes to atherosclerosis by exacerbating inflammation, cell infiltration, and apoptosis within atherosclerotic plaques.
  • Targeting PHD3 may offer a therapeutic strategy for atherosclerosis by mitigating endothelial cell damage and inflammatory processes.